Faye Kosmopolou of Greek generic industry association PEF discusses Greece’s potential as a pharma manufacturing hub for Southeast Europe post-COVID, the challenges of overcoming low generic penetration rates in the domestic market, and why she is optimistic for the future of Greek pharma moving forward.
Greece is the only European country to have included the pharmaceutical industry within its RRF plan, which will allow the inflow of new funds into the country and lead to the opening of 12 new manufacturing sites, 16 new R&D facilities, and 32 new manufacturing units
